A Study In Adults With Moderate To Severe Dermatomyositis

NCT03181893

Last updated date
Study Location
Brigham and Women's Hospital - ACC
Boston, Massachusetts, 02115, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Dermatomyositis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Must have CDASI Activity score of greater than or equal to 14, and have failed at least 1 standard of care systemic treatment, (eg, corticosteroids).

- Confirmation of DM by the investigator and two of the following:

1. Gottron's papules;

2. Gottron's sign;

3. Heliotrope eruption;

4. Nailfold changes, (dilated capillary loops, capillary dropout, cuticular hypertrophy and/or rugged cuticles;

5. Photodistributed violaceous erythema, (skin that is exposed to sunlight and appears purplish/reddish, and patchy in appearance;

6. Positive DM serology -

- Post DM diagnosis; standard of care workup for DM must have been completed prior to entry into this research study.

- Willing to provide 6 biopsies during the course of the research study

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Investigator site staff or members of their family.


- Acute and Chronic present medical conditions


- Intake of greater than 15 mg of prednisone or equivalent per day


- Pregnant or breastfeeding females. Fertile men and women who will not comply with the
use of 2 effective birth control methods as per the research protocol


- Have required management of acute or chronic infections


- Have pre existing demyelinating disorder such as multiple sclerosis, or other severe
neurological deficits.


- Clinically significant lab abnormalities


- Any health condition that may be worsened by immunosuppression

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]com

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

DermatomyositisStudy of Tofacitinib in Refractory Dermatomyositis
NCT03002649
  1. Baltimore, Maryland
ALL GENDERS
18 Years+
years
MULTIPLE SITES
DermatomyositisA Study In Adults With Moderate To Severe Dermatomyositis
NCT03181893
  1. Boston, Massachusetts
  2. Boston, Massachusetts
  3. Boston, Massachusetts
  4. Birmingham, Alabama
  5. Phoenix, Arizona
  6. Scottsdale, Arizona
  7. Palo Alto, California
  8. Jacksonville, Florida
  9. Baltimore, Maryland
  10. Boston, Massachusetts
  11. Boston, Massachusetts
  12. Saint Louis, Missouri
  13. New York, New York
  14. New York, New York
  15. Cleveland, Ohio
  16. Portland, Oregon
  17. Portland, Oregon
  18. Portland, Oregon
  19. Philadelphia, Pennsylvania
  20. Murray, Utah
  21. Salt Lake City, Utah
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study In Adults With Moderate To Severe Dermatomyositis
Official Title  ICMJE A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS
Brief Summary A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Dermatomyositis
Intervention  ICMJE
  • Drug: PF-06823859 low
    A humanized immunoglobulin neutralizing antibody
  • Drug: Placebo Arm
    Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
  • Drug: PF-06823859 high
    A humanized immunoglobulin neutralizing antibody
Study Arms  ICMJE
  • Placebo Comparator: Placebo ARM
    Intervention: Drug: Placebo Arm
  • Experimental: PF-06823859 ARM high
    Intervention: Drug: PF-06823859 high
  • Experimental: PF-06823859 ARM low
    Intervention: Drug: PF-06823859 low
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 14, 2020)
52
Original Estimated Enrollment  ICMJE
 (submitted: June 7, 2017)
30
Estimated Study Completion Date  ICMJE April 21, 2022
Estimated Primary Completion Date April 21, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Must have CDASI Activity score of greater than or equal to 14, and have failed at least 1 standard of care systemic treatment, (eg, corticosteroids).
  • Confirmation of DM by the investigator and two of the following:

    1. Gottron's papules;
    2. Gottron's sign;
    3. Heliotrope eruption;
    4. Nailfold changes, (dilated capillary loops, capillary dropout, cuticular hypertrophy and/or rugged cuticles;
    5. Photodistributed violaceous erythema, (skin that is exposed to sunlight and appears purplish/reddish, and patchy in appearance;
    6. Positive DM serology -
  • Post DM diagnosis; standard of care workup for DM must have been completed prior to entry into this research study.
  • Willing to provide 6 biopsies during the course of the research study

Exclusion Criteria:

  • Investigator site staff or members of their family.
  • Acute and Chronic present medical conditions
  • Intake of greater than 15 mg of prednisone or equivalent per day
  • Pregnant or breastfeeding females. Fertile men and women who will not comply with the use of 2 effective birth control methods as per the research protocol
  • Have required management of acute or chronic infections
  • Have pre existing demyelinating disorder such as multiple sclerosis, or other severe neurological deficits.
  • Clinically significant lab abnormalities
  • Any health condition that may be worsened by immunosuppression
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03181893
Other Study ID Numbers  ICMJE C0251002
2020-004228-41 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP